These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21877876)

  • 1. Prevention of contrast-induced nephropathy with haemofiltration in high-risk patients after percutaneous coronary intervention.
    Rey JR; Iglesias D; López De Sá E; Armada E; Moreno R; Salvador O; Monedero Mdel C; Blas SG; Iniesta AM; López-Sendon JL
    Acute Card Care; 2011 Sep; 13(3):164-9. PubMed ID: 21877876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
    Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
    Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
    Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
    Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
    Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
    Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of contrast-induced nephropathy in chronic total occlusion percutaneous coronary intervention.
    Lin YS; Fang HY; Hussein H; Fang CY; Chen YL; Hsueh SK; Cheng CI; Yang CH; Chen CJ; Hang CL; Yip HK; Wu CJ
    EuroIntervention; 2014 Feb; 9(10):1173-80. PubMed ID: 24561734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing of iodinated contrast volume: a new simple algorithm to stratify the risk of contrast-induced nephropathy in patients with acute coronary syndrome.
    Raposeiras-Roubín S; Abu-Assi E; Ocaranza-Sánchez R; Alvarez-Álvarez B; Cambeiro-González C; Fandiño-Vaquero R; García-Castelo A; García-Acuña JM; González-Juanatey JR
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):888-97. PubMed ID: 23362013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI.
    Wickenbrock I; Perings C; Maagh P; Quack I; van Bracht M; Prull MW; Plehn G; Trappe HJ; Meissner A
    Clin Res Cardiol; 2009 Dec; 98(12):765-72. PubMed ID: 19851800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention.
    Kandula P; Shah R; Singh N; Markwell SJ; Bhensdadia N; Navaneethan SD
    Nephrology (Carlton); 2010 Mar; 15(2):165-70. PubMed ID: 20470274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
    Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
    Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk score for contrast induced nephropathy following percutaneous coronary intervention.
    Ghani AA; Tohamy KY
    Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):240-5. PubMed ID: 19237811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.
    Ivanes F; Isorni MA; Halimi JM; Fauchier L; Saint Etienne C; Babuty D; Angoulvant D; Brunet-Bernard A
    Arch Cardiovasc Dis; 2014; 107(8-9):424-32. PubMed ID: 25082735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
    Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
    J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention.
    Uddin MA; Rabbani MA; Jafary FH; Bhatti MA; Islam M
    J Coll Physicians Surg Pak; 2005 Dec; 15(12):791-4. PubMed ID: 16398973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome.
    Senoo T; Motohiro M; Kamihata H; Yamamoto S; Isono T; Manabe K; Sakuma T; Yoshida S; Sutani Y; Iwasaka T
    Am J Cardiol; 2010 Mar; 105(5):624-8. PubMed ID: 20185007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention.
    Liu Y; Tan N; Zhou YL; Chen YY; Chen JY; Chen J; Luo JF
    J Nephrol; 2012; 25(3):332-40. PubMed ID: 21928234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volume-to-creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: implications of varying definitions of contrast-induced nephropathy.
    Capodanno D; Ministeri M; Cumbo S; Dalessandro V; Tamburino C
    Catheter Cardiovasc Interv; 2014 May; 83(6):907-12. PubMed ID: 23934631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.
    Zhang J; Fu X; Jia X; Fan X; Gu X; Li S; Wu W; Fan W; Su J; Hao G; Jiang Y; Xue L
    Acta Radiol; 2010 Jul; 51(6):641-8. PubMed ID: 20438292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.